Orexigen To Host Conference Call At 8:30 A.M. Eastern Time Today To Discuss Acquisition Of U.S. Rights To Contrave (naltrexone HCl / bupropion HCl extended release) And Central And Eastern Europe Distribution Agreement With Valeant

SAN DIEGO, March 15, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) will host a conference call this afternoon to discuss the strategic acquisition of all U.S. rights to Contrave^® and the Mysimba^® commercialization and distribution agreement with Valeant Pharmaceuticals International, Inc. for Central and Eastern Europe.

The call will be held today at 8:30 a.m. ET / 5:30 a.m. PT and may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 42093506. The webcast can be accessed live on the Investors section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/orexigen-therapeutics-to-host-conference-call-at-830-am-eastern-time-today-to-discuss-acquisition-of-us-rights-to-contrave-naltrexone-hcl--bupropion-hcl-extended-release-and-central-and-eastern-europe-distribution-agreeme-300236043.html

SOURCE Orexigen Therapeutics, Inc.